A growing body of research underscores the value of ctDNA-based MRD testing to identify residual or recurring cancer in solid tumors. By detecting trace amounts of tumor-derived DNA in the bloodstream ...
SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (DGX) company, today announced a research collaboration with Mass General Brigham investigators at ...
SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer ...
Haystack Oncology, a Quest Diagnostics Inc. (NYSE:DGX) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:LSTA). Haystack Oncology developed Haystack MRD, a ...
(RTTNews) - Quest Diagnostics (DGX), a provider of diagnostic information services, announced Monday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for ...
Oncologists face a difficult decision after surgically removing a solid tumor. Some patients harbor residual cancer cells, known as minimal residual disease (MRD), and need additional therapy to avoid ...
Title: Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC). A growing body of research underscores ...
SECAUCUS, N.J., Jan. 6, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results